Detalhe da pesquisa
1.
The Effects of GCSF Primary Prophylaxis on Survival Outcomes and Toxicity in Patients with Advanced Non-Small Cell Lung Cancer on First-Line Chemoimmunotherapy: A Sub-Analysis of the Spinnaker Study.
Int J Mol Sci
; 24(2)2023 Jan 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-36675262
2.
Immunotherapy-related adverse events in real-world patients with advanced non-small cell lung cancer on chemoimmunotherapy: a Spinnaker study sub-analysis.
Front Oncol
; 13: 1163768, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37324003
3.
Efficacy outcomes and prognostic factors from real-world patients with advanced non-small-cell lung cancer treated with first-line chemoimmunotherapy: The Spinnaker retrospective study.
Int Immunopharmacol
; 110: 108985, 2022 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-35777264
4.
Pembrolizumab in patients with non-small-cell lung cancer of performance status 2 (PePS2): a single arm, phase 2 trial.
Lancet Respir Med
; 8(9): 895-904, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32199466
5.
Decrease of serum carnitine levels in patients with or without gastrointestinal cancer cachexia.
World J Gastroenterol
; 12(28): 4541-5, 2006 Jul 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-16874868
6.
Single agent panitumumab in KRAS wild-type metastatic colorectal cancer patients following cetuximab-based regimens: Clinical outcome and biomarkers of efficacy.
Cancer Biol Ther
; 14(12): 1098-103, 2013 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-24025413
7.
Bifidobacterium longum with fructo-oligosaccharide (FOS) treatment in minimal hepatic encephalopathy: a randomized, double-blind, placebo-controlled study.
Dig Dis Sci
; 52(11): 3259-65, 2007 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-17393330